Bemarituzumab

贝马妥珠单抗

Report date: 2026/04/24 20:01:59

Base Information

Drug NameBemarituzumab
Drug Alias NameFPA-144AMG-552
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Fibroblast Growth Factor Receptor 2b
TargetsFibroblast Growth Factor Receptor 2b
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGalaxy Biotech
China Registration ClassN/A

Develop Information

Active CompaniesZai Lab (Us) LlcFive Prime Therapeutics IncZai Lab (Shanghai) Co Ltd +[6] 
Inactive CompaniesAmgen UK LtdInstitut De Cancerologie De L OuestCentre Leon Berard
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[4] 
Inactive IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A